disease (risk of recurrence: 13.1%). While, having HPV persistence >12 months did not correlate with an increased risk of recurrence (HR: 1.34 (95%CI: 0.78, 2.32); p=0.336, log-rank test).

Conclusion HPV persistence is one of the most important factor predicting the risk of CIN2+ recurrence. The risk of CIN2+ recurrence increased by the increase of HPV persistence up to one year. The persistence of HPV after the first year does not appear as a risk factor.

**2022-RA-743-ESGO**

**IMPROVING RISK STRATIFICATION FOR CERVICAL CANCER IN PATIENTS TREATED WITH CONCURRENT CHEMORADIATION AND MRI-IMAGE GUIDED ADAPTIVE BRACHYTHERAPY IN EMBRACE STUDY: RESULTS FROM AN INTERNATIONAL COLLABORATIVE TRANSLATIONAL RESEARCH STUDY (BIOEMBRACE-I)**

1Supriya Chopra, 2Ekaterina S Jordanova, 3Nanda Horeweg, 3Kedar Deodhar, 4Santosh Menon, 5Venkateesh Pai, 2Sraitha Rafael, 6Umesh Mahantshetty, 7Barbara Segedín, 8Nadia Giannakopoulou, 9Fleur Huang, 10Kjirsti Bruheim, 11Marga Perz, 12Bhavana Rai, 13Li Tee Tan, 14Maximilian Schmid, 15Kari Tanderup, 16Richard Potter, 17Tjalling Bosse, 18Remi A Nout. 1Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India; 2Leiden University Medical Centre, Leiden, Netherlands; 3Tata Memorial Hospital, Tata Memorial Centre, Mumbai, India; 4Tata Memorial Hospital, Tata Memorial Centre, Mumbai, India; 5ACTREC, Tata Memorial Centre, Navi Mumbai, India; 6Institute of Oncology, Ljubljana, Slovenia; 7Cross Cancer Institute, Edmonton, AB, Canada; 8Oslo University Hospital, Oslo, Norway; 9Navarre Biobanco, Centro De Investigacion Biomédica, Pamplona, Spain; 10Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India; 11Cambridge University Hospital, Addenbrooke, UK; 12Medical University Vienna, Vienna, Austria; 13Aarhus University Hospital, Aarhus University, Denmark; 14Medical University of Vienna, Vienna, Austria; 15Erasmus University Medical Centre, Rotterdam, Netherlands

10.1136/ijgc-2022-ESGO.55

**Introduction/Background** BIOEMBRACE-I is a translational sub-study of EMBRACE-I, initiated to improve risk stratification for cervical cancer patients treated with chemoradiation and MRI-guided brachotherapy

**Methodology** Between 2018–2021, patients were included from EMBRACE study sites. Prognostic factors at baseline and brachtherapy (FIGO stage, nodal involvement, histology, necrosis on MR, poor response indicated by high risk clinical target volume at brachtherapy (HRCTV-BT > 40 cc) were included. In the first phase, immunohistochemistry for p16 and L1CAM was performed. p16 was categorized as positive or negative and LI-CAM was categorized as 0–10%, 10–50% or 50% overexpression.

Response to EBRT and disease outcomes were tested after including p16 and LI-CAM along with other prognostic factors. Univariate and multivariable analysis (MVA) was performed.

**Results** Eight EMBRACE sites included 264 patients with a median follow up of 50 months (21–67). Distribution of prognostic factors, including p16 and LI-CAM expression is summarized in Table 1. The median HRCTV-BT and D90 was 30 cm³ (IQR 22–44) and 89 Gy (IQR 86–95 Gy). p-16 positive patients had higher nodal positivity (96% vs. 3%, p=0.0001) or necrosis on MRI (73% vs. 26%, p=0.01) and proportion of HRCTV-BT < 40cc (72.8% vs. 54.5%, p=0.03). The 5-year pelvic, disease control and disease free survival (DFS) was 87.3%, 72.6% and 66.7% respectively. On MVA, FIGO stage (HR=5.4, p<0.0001), necrosis on MR (HR =2.6, p=0.005) and p-16 negative status (HR=2.1, p=0.07) predicted for HRCTV-BT > 40cc. For pelvic and disease control HRCTV-BT > 40cc and L1CAM > 50% were independent predictors, though reduced pelvic control was also observed at L1CAM >10% on univariate analysis. For DFS, nodal status and HRCTV-BT > 40cc were independent predictors (table 1).

**Conclusion** FIGO stage, necrosis on MR and p16 negative status predicted for HRCTV-BT > 40 cc. HRCTV-BT > 40 cc and L1CAM are prognostic for pelvic and disease control. PDL-1 analysis is ongoing.

**2022-RA-755-ESGO**

**COMPARISON OF PD-L1 STATUS BETWEEN PRIMARY AND PAIRED RECURRENT/METASTATIC CERVICAL CANCER**

1Beyhan Ataseven, 2Timoleon Dogr, 3Florian Hertz, 4Nicole Concin, 5Theresa Thomas, 6Majdi Imterat, 7Nina Pauly, 8Sebastian Helkau, 9Alexander Traut, 10Malak Moubarak, 11Philipp Harter. 1Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany; 2Klinikum Essen-Mitte, Essen, Germany; 3Centrum of Pathology Essen-Mitte, Essen, Germany; 4ACTREC, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, India; 5Medical University of Vienna, Vienna, Austria; 6Institute of Oncology, Ljubljana, Slovenia; 7Cross Cancer Institute, Edmonton, AB, Canada; 8Oslo University Hospital, Oslo, Norway; 9Navarre Biobanco, Centro De Investigacion Biomédica, Pamplona, Spain; 10Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India; 11Cambridge University Hospital, Addenbrooke, UK

10.1136/ijgc-2022-ESGO.56

**Introduction/Background** Randomized trials established the clinical benefit of PD-1-inhibitors in recurrent/metastatic cervical cancer (CC). However, this benefit seems to be restricted mainly to PD-L1-positive CC. The purpose of this study was to compare the PD-L1-status in primary CC with a paired sample at the time of recurrent/metastatic disease.

**Methodology** PD-L1-scoring was analyzed by immunohistochemistry (Ventana PD-L1 (SP263) in archived tumor tissue of primary CC and paired recurrent/metastatic CC (n= 24). PD-L1-posivity was defined as CPS (combined positive score) ≥1.

**Results** 50% (12/24) of patients were in FIGO stage IB1-IIA2 at primary diagnosis and the majority had squamous cell histology (87.5%; 21/24). Median PFS was 8.9 (95% CI: 7.8–10.0) months.PD-L1-CPS ≥1 was found in 96% (23/24) of primary and 92% (22/24) of paired recurrent/metastatic CC. The median CPS was 22 (range 0–80) in primary and 20 (range 0–90) in recurrent/metastatic CC. Correlation between primary and recurrent/metastatic CC was high (0.79). Only in one case a shift from a CPS-positive primary to CPS-negative relapsed disease was detected.

**Conclusion** Comparing PD-L1-status (CPS) between primary and recurrent/metastatic CC demonstrated a high concordance. Our data indicate, that PD-L1 testing in archival material from primary tumor is sufficient, if a fresh sample at relapse or of metastases is not available.